Shire PLC (LON:SHP)

Shire Plc is a specialty biopharmaceutical company that focuses on developing and marketing innovative specialty medicines that address unmet patient needs. The Company’s products included VYVANSE/VENVANSE (lisdexamfetamine dimesylate), ADDERALL XR (mixed salts of a single-entity amphetamine), INTUNIV (extended release guanfacine), EQUASYM (methylphenidate hydrochloride) modified release (XL), LIALDA (mesalamine)/ MEZAVANT(mesalazine), PENTASA (mesalamine), RESOLOR (prucalopride), FOSRENOL (lanthanum carbonate), XAGRID (anagrelide hydrochloride), REPLAGAL (agalsidase alfa), ELAPRASE (idursulfase), VPRIV (velaglucerase alfa), FIRAZYR (icatibant) and DERMAGRAFT(Human Fibroblast-Derived Dermal Substitute), CINRYZE. The Company focuses its development resources on projects in a number of therapeutic areas, including Neuroscience, Rare Diseases, Ophthalmology, Hematology and GI, and focuses its early development projects on rare diseases.

Official website: www.shire.com